To address these concerns, the research team developed a decision-analytical model to estimate how relabeling GG1 disease ...
What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade ...
(HealthDay News) — Prostate-specific antigen (PSA) screening likely results in a reduction in prostate cancer-specific mortality, according to a review published online May 15 in the Cochrane Database ...
"ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC" was originally created and published by ...
2don MSN
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...
Routine prostate cancer screening has been rejected by the UK's independent screening committee despite significant pressure ...
NHS advisors have again rejected pleas for potentially life-saving routine prostate cancer screening after concluding that ...
Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.
Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...
A dose reduction of Erleada may result in fewer skin-related side effects for men with advanced prostate cancer — but only for those with a smaller body size, research showed. A dose reduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results